Van beleggers
voor beleggers
desktop iconMarkt Monitor


  • Geen account? Registreren

Wachtwoord vergeten?

Aandeel OXURION BRU:OXUR.BL, BE0003846632

  • 1,800 14 jan 2022 17:29
  • -0,024 (-1,32%) Dagrange 1,784 - 1,828
  • 19.273 Gem. (3M) 38,6K


172 Posts
Pagina: «« 1 2 3 4 5 6 ... 9 »» | Laatste | Omlaag ↓
  1. Handelenwandel 6 april 2021 08:50
    Vanmorgen in de mailbox:

    Oxurion NV

    Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group

    Leuven, BE, Boston, MA, US – April 6, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care back of the eye therapies, today announces that is has agreed to a capital commitment of up to €30 Million with Negma Group.
    Negma Group is a Paris-based leading financial institution focused on supporting growth and capturing value through a multi-strategy approach.
    Negma Group has committed to subscribe to up to €30 million in equity in tranches over a 12-month period through mandatory convertible bonds at Oxurion’s sole discretion.

    Oxurion anticipates initial clinical data from its lead drug candidate THR-149 later this year. THR-149 is a plasma kallikrein inhibitor being developed as a potential new standard of care for diabetic macular edema (DME) patients, who respond sub-optimally to anti-VEGF therapy.

    Oxurion also expects to initiate a Phase 2 clinical trial with THR-687 in DME by mid-year. THR-687 is a pan-RGD integrin inhibitor that is being developed as a potential first line therapy for all DME patients. THR-687 also holds potential to deliver improved treatment outcomes for patients with wet Age-related Macular Degeneration (wet AMD) and Retinal Vein Occlusion (RVO).

    Patrik De Haes, M.D., CEO of Oxurion, says: “I am happy that we have been able to agree on this flexible financing agreement, which is under our control and can be exercised at our discretion. Access to these funds will allow us to focus on progressing our two exciting novel and differentiated back of the eye drug candidates that are targeting potential market opportunities of over $12 billion, beyond key value inflection points in 2021 and 2022.”

    “We are excited to collaborate with Oxurion. At Negma Group, we invest in people and have been very impressed by both the scientific rigor and clinical experience of the Oxurion team. We are proud to partner with this team while they advance two very distinct and innovative programs that have great potential to deliver much improved clinical outcomes to patients suffering from debilitating retinal vascular disorders such as DME, wet AMD and RVO”, says Sophie Villedieu, Equity Capital Market Associate of Negma Group.

    Lijkt mij in de basis goed nieuws, hoewel ze dit bedrag op zo'n termijn nooit kunnen terugbetalen dus aansluitend achter nieuwe funding aan zullen moeten of het omzetten naar aandelen?
    Wat denken jullie
  2. forum rang 6 JdeFL 6 april 2021 09:16
    Ben op de website gaan kijken, maar helaas staat er geen prijs per aandeel bij. 'at Oxurion’s sole discretion.' Cryptisch.
    Ophalen van kapitaal, bedrag 30M, maar hoeveel aandelen? Mogelijks met een formule, telkens gemiddelde koers van de maand, met korting. Wordt in schijven gedaan, eerste hint zou dus binnen een maand schijnen...
  3. forum rang 6 JdeFL 6 april 2021 11:00
    • Oxurion gaat een kapitaalverbintenis van maximaal 30 miljoen euro aan met Negma Group, een Parijsefinanciële instelling die zich richt op het ondersteunen van groei en het creëren van waarde door middel van een multi-strategische aanpak. De kapitaalsinjectie bestaat uit verschillende tranches over een periode van 12 maanden, via verplichte converteerbare obligaties, naar eigen goeddunken van Oxurion.
    Die verwacht later dit jaar de eerste klinische gegevens van haar voornaamste kandidaat-geneesmiddel THR-149, dat diabetisch maculair oedeem moet helpen behandelen. Deze bijkomende financiering versterkt de kaspositie van het bedrijf, die in december nog 25 miljoen euro bedroeg, en maakt de verdere klinische ontwikkeling van de twee Fase II-activa mogelijk. Geen impact op 3 euro koersdoel en “Houden”-advies.
    • (Bolero)
  4. Handelenwandel 7 april 2021 18:30
    Zal wel geen toeval zijn het PB van gisteren maar wel mooi nieuws!
    Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD

    Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorders - THR-687 on track to enter Phase 2 development by mid-year

    Leuven, BE, Boston, MA, US – April 7, 2021 – 05.45 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care therapies for retinal vascular disorders, announces the publication of a review article describing the cutting-edge science and rationale for the design and development of THR-687. The article entitled: Targeting RGD-binding integrins as an integrative therapy for diabetic retinopathy and neovascular age-related macular degeneration’ (I Van Hove et al, reference below) was published in Progress in Retinal Eye Research.

    Integrins are a class of transmembrane receptors that are involved in a wide range of biological functions. The authors describe how RGD integrins affect a multitude of disease-related proteins and molecular pathways in relation to retinal vascular disorders. RGD integrins have been demonstrated to play an important role in diabetic retinopathy (DR), age-related macular degeneration (AMD), glaucoma, dry eye disease and retinal vein occlusion (RVO).

    Based on these findings, the authors conclude that therapies that engage integrin-linked pathways, including THR-687, have the potential to block all of these pathways and to deliver important clinical benefits to patients with these vision threatening conditions.

    Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorders, with THR-687, a potential best-in-class molecule on track to enter a Phase 2 study in patients with diabetic macular edema (DME) in mid-2021. Oxurion is initially developing THR-687 as a first line therapy for DME. THR-687 also holds potential for development in wet AMD and RVO.

    Prof Alan Stitt, Ph.D., Chief Scientific Officer (CSO) of Oxurion, said, “We are pleased to have made this important scientific contribution to retinal eye research. Selective integrin antagonists are becoming an ever-more attractive option to block key processes such as vasopermeability, neovascularisation and inflammation to prevent sight-loss, a therapeutic area in which Oxurion is well placed. The review highlights the potential of our pioneering pan-RGD integrin antagonist THR-687 to deliver important clinical benefits to patients with retinal vascular disorders. We are on track to start a Phase 2 study in patients with DME in mid-year, and we are excited by the significant potential of THR-687 to provide a broad therapeutic alternative for retinal vascular diseases including DME, wet AMD and RVO.”

  5. forum rang 6 JdeFL 12 april 2021 10:35
    • Oncurious heeft samen met partner BioInvent International de gegevens voorgesteld van een fase Idosisescalatiestudie van TB-403 bij pediatrische proefpersonen met recidiverend of refractair
    medulloblastoom (MB). Dat gebeurde op de jaarlijkse bijeenkomst van de American Association for
    Cancer Research (AACR). De resultaten rechtvaardigen een verdere evaluatie van TB-403, dat door het Europees Geneesmiddelenbureau (EMA) de status van weesgeneesmiddel verkreeg. Het middel is wel niet langer één van BioInvent’s focusprojecten: de groep draagt geen ontwikkelingskosten meer, maar heeft wel de rechten op 50 procent van de toekomstige inkomsten na aftrek van een deel van de vroegere, en alle toekomstige, ontwikkelingskosten met betrekking tot TB-403 (bolero)

  6. Handelenwandel 12 april 2021 11:14
    Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in Paediatric Subjects with Relapsed or Refractory Medulloblastoma Presented at the American Association for Cancer Research 2021 Annual Meeting

    Leuven, Belgium, Boston, MA, US, 12 April 2021 – 7.30 AM CET – ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative oncology treatments, today announces that encouraging data from a Phase 1 dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB), was presented at the annual meeting of the American Association for Cancer Research (AACR).

    The data was presented by Dr. Giselle Sholler, Director, Isabella Santos Foundation Solid and Rare Tumor Program, Chair at Beat Childhood Cancer Research Consortium, and Professor, Paediatric Oncology at the Levine Children’s Hospital in Charlotte, NC.

    The Phase 1 trial (ONC-403-001) was an open--label, multi-center, dose escalation study of TB--403 in a total of 15 pediatric subjects - 11 with relapsed or refractory MB, 2 with Ewing Sarcoma (ES) and 2 with alveolar rhabdomyosarcoma (ARMS). The study was conducted in conjunction with the Beat Childhood Cancer Research Consortium, Massachusetts General Hospital and Atrium Health Levine Children's Hospital.

    The study evaluated 4 dose levels of TB-403: 20 mg/kg, 50 mg/kg, 100 mg/kg, and 175 mg/kg. The dose limiting toxicity (DLT) assessment cycle for the study was 28 days with subjects receiving 2 doses of TB-403 at Day 1 and Day 15 respectively. After the DLT period, temozolomide or etoposide could be added to the subject’s treatment regimen.

    Evaluations for the response to TB-403 were made at the end of cycle 1 and every 2 cycles thereafter.

    The key safety findings from the study were as follows:
    TB-403 was safe and well tolerated at all dose levels: no maximum tolerated dose (MTD) was reached
    TB-403 exposure of children is in accordance with the exposure of the drug in adults
    TB-403 exposure and concentration increased dose-proportionally over the dose range of 20-175 mg/kg

    The key response findings were as follows:
    At the 3 highest dose levels of TB-403, 7 out of 8 of medulloblastoma patients had stable disease
    4 medulloblastoma patients had prolonged stabilization of disease > 100 days

    Exploratory biomarker analysis showed a decrease in plasma levels of free placental growth factor (PlGF) to undetectable levels at all doses of TB-403, with no apparent changes in other angiogenic or inflammatory factors.

    The results of the Phase 1 study warrant further evaluation of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB).

    Dr. Giselle Sholler, Chair at Beat Childhood Cancer Research Consortium, commented: ”I am pleased that the Beat Childhood Cancer Research Consortium has been able to play a key role in this important study. The encouraging data that I presented at AACR show that treatment with TB-403 can produce a clinically meaningful response in a significant number of children with relapsed and refractory medulloblastoma. The encouraging results, in what is a very difficult to treat patient population, warrant further clinical investigation, and we at the Beat Childhood Cancer Research Consortium would be happy to play our role in any such effort.”

    TB-403 is a humanized monoclonal antibody against PlGF which is expressed in several types of cancer, including medulloblastoma. A paper in Cell (Cell, 152, 1065-76, 2013), highlighted that PlGF plays a role in the growth of medulloblastoma. The paper was based on preclinical research conducted by Prof Rakesh Jain from the Massachusetts General Hospital at Harvard (Boston) and the team of Prof Dr. Peter Carmeliet from the VIB/ KU Leuven.

    Prof Dr. Peter Carmeliet from the VIB/ KU Leuven, added, ”I am pleased that our preclinical research showing that PlGF plays a key role in the growth of medulloblastoma has been confirmed in this Phase 1 clinical study with TB-403. I look forward to following the further clinical development of this novel PIGF inhibitor and am confident that it has the potential to benefit children suffering from this devastating brain cancer.”

    Dr. Patrik De Haes, Executive Chairman of Oncurious said, “I would like to thank everyone who has taken part in the execution of this successful study with TB-403, especially the patients and their families. The data that has been generated show that TB-403 could expand the treatment options for children with relapsed and refractory medulloblastoma. Meanwhile, Oncurious’ international patent application, published with a positive indication on the patentability of the combination of TB-403 with etoposide or temozolomide, and expiring as late as 2040, puts Oncurious in a good position to evaluate potential partnering options for future development and manufacturing of TB-403.”

    Hier het hele mail bericht, geen idee hoe we dit nu allemaal moeten duiden, is dit omdat het in Brussel genoteerd staat dat er nauwelijks koers reactie is? Voor mijn gevoel had dit in AMS voor dubbele cijfers stijging kunnen zorgen?

    Los van dat het mij geweldig nieuws lijkt voor de patiënten, zeker ook de kinderen die het betreft dat er zicht zou kunnen zijn op een behandeling.
172 Posts
Pagina: «« 1 2 3 4 5 6 ... 9 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum


Koers 1,800   Verschil -0,02 (-1,32%)
Laag 1,784   Volume 19.273
Hoog 1,828   Gem. Volume 38.643
14 jan 2022 17:29


Het laatste advies leest u als IEX Premium-lid

Ontdek Premium

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links